• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by SWK Holdings Corporation

    4/8/26 6:31:29 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 17)


    SWK HOLDINGS CORPORATION

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    78501P203

    (CUSIP Number)
    Carlson Capital, L.P.
    Attn: Rahim Ibrahim, 2100 McKinney Avenue
    Dallas, TX, 75201
    (214) 932-9600

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/06/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    78501P203


    1 Name of reporting person

    Double Black Diamond Offshore Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP Number(s):
    78501P203


    1 Name of reporting person

    Carlson Capital, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    PN, IA



    SCHEDULE 13D

    CUSIP Number(s):
    78501P203


    1 Name of reporting person

    Asgard Investment Corp. II
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP Number(s):
    78501P203


    1 Name of reporting person

    Asgard Investment Corp.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP Number(s):
    78501P203


    1 Name of reporting person

    Clint D. Carlson
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    SWK HOLDINGS CORPORATION
    (c)Address of Issuer's Principal Executive Offices:

    5956 Sherry Lane, Suite 650, Dallas, TEXAS , 75225.
    Item 1 Comment:
    Explanatory Note This Amendment No. 17 ("Amendment No. 17") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on November 4, 2009 (the "Original Schedule 13D"), as amended by Amendment No. 1 to the Original Schedule 13D filed with the SEC on November 25, 2009 ("Amendment No. 1"), and as further amended by Amendment No. 2 to the Original Schedule 13D filed with the SEC on March 1, 2012 ("Amendment No. 2"), and as further amended by Amendment No. 3 to the Original Schedule 13D filed with the SEC on September 9, 2013 ("Amendment No. 3"), and as further amended by Amendment No. 4 to the Original Schedule 13D filed with the SEC on May 16, 2014 ("Amendment No. 4"), and as further amended by Amendment No. 5 to the Original Scheduled 13D filed with the SEC on June 23, 2014 ("Amendment No. 5"), and as further amended by Amendment No. 6 to the Original Schedule 13D filed with the SEC on July 16, 2014 ("Amendment No. 6"), and as further amended by Amendment No. 7 to the Original Schedule 13D filed with the SEC on August 19, 2014 ("Amendment No. 7"), and as further amended by Amendment No. 8 to the Original Schedule 13D filed with the SEC on December 8, 2014 ("Amendment No. 8"), and as further amended by Amendment No. 9 to the Original Schedule 13D filed with the SEC on March 30, 2018 ("Amendment No. 9), and as further amended by Amendment No. 10 to the Original Schedule 13D filed with the SEC on April 6, 2021 ("Amendment No. 10"), and as further amended by Amendment No. 11 to the Original Schedule 13D filed with the SEC on May 18, 2021 ("Amendment No. 11"), and as further amended by Amendment No. 12 to the Original Schedule 13D filed with the SEC on November 12, 2021 ("Amendment No. 12"), and as further amended by Amendment No. 13 to the Original Schedule 13D filed with the SEC on November 23, 2021 ("Amendment No. 13") and as further amended by Amendment No. 14 to the Original Schedule 13D filed with the SEC on December 28, 2021 ("Amendment No. 14"), and as further amended by Amendment No. 15 to the Original Schedule 13D filed with the SEC on January 7, 2022 ("Amendment No. 15"), and as further amended by Amendment No. 16 to the Original Schedule 13D filed with the SEC on October 23, 2024 ("Amendment No. 16, and together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8, Amendment No. 9, Amendment No. 10, Amendment No. 11, Amendment No. 12, Amendment No. 13, Amendment No. 14, Amendment No. 15, Amendment No. 16 and this Amendment No. 17, the "Schedule 13D"), with respect to the shares of common stock ("Shares"), par value $0.001 per share, of SWK Holdings Corporation (the "Issuer"). Capitalized terms used herein and not otherwise defined in this Amendment No. 17 have the meanings set forth in the Schedule 13D. This Amendment No. 17 amends Items 4, 5 and 6 as set forth below.
    Item 4.Purpose of Transaction
     
    The information previously provided in response to Item 4 is hereby amended and supplemented by adding the following information: On April 6, 2026, pursuant to the Agreement and Plan of Merger dated as of October 9, 2025 (the "Merger Agreement"), Runway Growth Finance Corp. ("Parent"), RWAY Portfolio Holding Corp., RWAY Portfolio Corp. ("Acquisition Sub"), Runway Growth Capital LLC ("Adviser") and SWK Holdings Corporation ("SWK") effected a merger pursuant to which SWK was merged with and into Acquisition Sub (the "First Merger"). Pursuant to the Merger Agreement, upon completion of the First Merger (the "Effective Time"), each issued and outstanding common stock of SWK ("SWK Common Stock") was cancelled and converted into the right to receive (i) either (A) 1.7264 shares of common stock, par value $0.01 per share, of Parent ("Parent Common Stock" and such consideration, the "Per Share Stock Consideration") or (B) $20.59 in cash (the "Per Share Cash Consideration") (in each case, based on the election of the holder thereof in accordance with the terms of the Merger Agreement and subject to proration as provided therein) plus (ii) $0.74 in cash, which represents a pro rata share of the guaranteed cash payment paid by the Adviser (the "Per Share Guaranteed Cash Payment" and collectively with the Per Share Stock Consideration and the Per Share Cash Consideration, the "Total Per Share Consideration"). As a result, the Reporting Persons no longer beneficially own any shares of the Issuer.
    Item 5.Interest in Securities of the Issuer
    (a)
    Pursuant to the closing of the merger described in Item 4, the Reporting Persons beneficially owned an aggregate of 0 Shares, constituting approximately 0% of the Shares outstanding. The aggregate percentage of Shares reported in this Amendment No. 17 are based on an aggregate number of 12,095, 906 Shares outstanding as of March 2, 2026, as reported in the Issuer's 8-K filed with the SEC on March 3, 2026.
    (c)
    No transactions were effected by the Reporting Persons in the Shares since the filing of Amendment No. 16.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The information previously provided in response to Item 6 is hereby amended and supplemented by adding the following information: Item 4 of this Amendment No. 17 is hereby incorporated by reference.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Double Black Diamond Offshore Ltd.
     
    Signature:/s/ Clint D. Carlson
    Name/Title:By: Carlson Capital, L.P., its investment manager, By: Asgard Investment Corp. II, its general partner, Clint D. Carlson, President
    Date:04/08/2026
     
    Carlson Capital, L.P.
     
    Signature:/s/ Clint D. Carlson
    Name/Title:By: Asgard Investment Corp. II, its general partner, Clint D. Carlson, President
    Date:04/08/2026
     
    Asgard Investment Corp. II
     
    Signature:/s/ Clint D. Carlson
    Name/Title:Clint D. Carlson, President
    Date:04/08/2026
     
    Asgard Investment Corp.
     
    Signature:/s/ Clint D. Carlson
    Name/Title:Clint D. Carlson, President
    Date:04/08/2026
     
    Clint D. Carlson
     
    Signature:/s/ Clint D. Carlson
    Name/Title:Clint D. Carlson
    Date:04/08/2026
    Get the next $SWKH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    ImpediMed Secures $15m Growth Capital Funding

    New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

    2/7/25 11:00:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Carlson Capital, L.P.

    4 - SWK Holdings Corp (0001089907) (Issuer)

    4/8/26 7:00:09 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Hatcher Robert K. was granted 3,858 shares, increasing direct ownership by 30% to 16,662 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:45 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Albright Jerry was granted 3,858 shares, increasing direct ownership by 55% to 10,832 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on SWK Holdings with a new price target

    Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    12/28/22 9:18:49 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Lake Street initiated coverage on SWK Holdings with a new price target

    Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    4/18/22 8:44:23 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    SEC Filings

    View All

    SEC Form EFFECT filed by SWK Holdings Corporation

    EFFECT - SWK Holdings Corp (0001089907) (Filer)

    4/9/26 12:15:04 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form EFFECT filed by SWK Holdings Corporation

    EFFECT - SWK Holdings Corp (0001089907) (Filer)

    4/9/26 12:15:02 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Amendment: SEC Form SCHEDULE 13D/A filed by SWK Holdings Corporation

    SCHEDULE 13D/A - SWK Holdings Corp (0001089907) (Subject)

    4/8/26 6:31:29 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    View All

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    1/22/25 8:30:00 AM ET
    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance

    SWK Holdings Appoints Chief Financial Officer

    Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

    7/8/24 5:00:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    11/14/24 11:49:47 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

    SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

    10/25/24 4:05:56 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    2/14/24 2:14:12 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Financials

    Live finance-specific insights

    View All

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

    Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

    11/14/24 4:15:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SWK Holdings Provides Portfolio Update

    Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

    10/17/24 4:15:00 PM ET
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)